# CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

## Metadata
**Authors:** Yasmin Schmid, Patrick Vizeli, Cédric M Hysek, Katharina Prestin, Henriette E Meyer zu Schwabedissen, Matthias E Liechti
**Journal:** Pharmacogenetics and Genomics
**Date:** 2016 May 31
**DOI:** [10.1097/FPC.0000000000000231](https://doi.org/10.1097/FPC.0000000000000231)
**PMID:** 27253829
**PMCID:** PMC4949007
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949007/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC4949007/pdf/fpc-26-397.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC4949007/pdf/fpc-26-397.pdf)

## Abstract

Supplemental Digital Content is available in the text.

Keywords: cytochrome P450; CYP2D6; 4-hydroxy-3-methoxymethamphetamine; 3,4-methylene-dioxyamphetamine; 3,4-methylene-dioxymethamphetamine; pharmacokinetics

## Supplementary Material

## Acknowledgements

This study was supported by the Swiss National Science Foundation (grant no. 320030_1449493).

### Conflicts of interest

There are no conflicts of interest.

## Footnotes

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Supplementary Materials

### Supplementary Materials

## References

1. De la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farre M. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relvant? Front Genet 2012; 3:1–6.  [DOI](https://doi.org/10.3389/fgene.2012.00235) | [PMC free article](/articles/PMC3495276/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23162568/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Front%20Genet&title=MDMA,%20methamphetamine,%20and%20CYP2D6%20pharmacogenetics:%20what%20is%20clinically%20relvant?&author=R%20De%20la%20Torre&author=S%20Yubero-Lahoz&author=R%20Pardo-Lozano&author=M%20Farre&volume=3&publication_year=2012&pages=1-6&pmid=23162568&doi=10.3389/fgene.2012.00235&)

2. Rietjens SJ, Hondebrink L, Westerink RH, Meulenbelt J. Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions. Crit Rev Toxicol 2012; 42:854–876.  [DOI](https://doi.org/10.3109/10408444.2012.725029) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23030234/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Crit%20Rev%20Toxicol&title=Pharmacokinetics%20and%20pharmacodynamics%20of%203,4-methylenedioxymethamphetamine%20(MDMA):%20interindividual%20differences%20due%20to%20polymorphisms%20and%20drug%E2%80%93drug%20interactions&author=SJ%20Rietjens&author=L%20Hondebrink&author=RH%20Westerink&author=J%20Meulenbelt&volume=42&publication_year=2012&pages=854-876&pmid=23030234&doi=10.3109/10408444.2012.725029&)

3. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93:402–408.  [DOI](https://doi.org/10.1038/clpt.2013.2) | [PMC free article](/articles/PMC3689226/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23486447/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Clinical%20pharmacogenetics%20implementation%20consortium%20guideline%20for%20CYP2D6%20and%20CYP2C19%20genotypes%20and%20dosing%20of%20tricyclic%20antidepressants&author=JK%20Hicks&author=JJ%20Swen&author=CF%20Thorn&author=K%20Sangkuhl&author=ED%20Kharasch&volume=93&publication_year=2013&pages=402-408&pmid=23486447&doi=10.1038/clpt.2013.2&)

4. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 2006; 20:842–849.  [DOI](https://doi.org/10.1177/0269881106065907) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16714321/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Psychopharmacol&title=Implications%20of%20mechanism-based%20inhibition%20of%20CYP2D6%20for%20the%20pharmacokinetics%20and%20toxicity%20of%20MDMA&author=J%20Yang&author=M%20Jamei&author=A%20Heydari&author=KR%20Yeo&author=R%20de%20la%20Torre&volume=20&publication_year=2006&pages=842-849&pmid=16714321&doi=10.1177/0269881106065907&)

5. O’Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, et al. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 2008; 28:523–529.  [DOI](https://doi.org/10.1097/JCP.0b013e318184ff6e) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18794647/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Psychopharmacol&title=The%20consequences%20of%203,4-methylenedioxymethamphetamine%20induced%20CYP2D6%20inhibition%20in%20humans&author=B%20O%E2%80%99Math%C3%BAna&author=M%20Farr%C3%A9&author=A%20Rostami-Hodjegan&author=J%20Yang&author=E%20Cuy%C3%A0s&volume=28&publication_year=2008&pages=523-529&pmid=18794647&doi=10.1097/JCP.0b013e318184ff6e&)

6. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (‘ecstasy’) in humans. Clin Pharmacol Ther 2011; 90:246–255.  [DOI](https://doi.org/10.1038/clpt.2011.78) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21677639/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=The%20norepinephrine%20transporter%20inhibitor%20reboxetine%20reduces%20stimulant%20effects%20of%20MDMA%20(%E2%80%98ecstasy%E2%80%99)%20in%20humans&author=CM%20Hysek&author=LD%20Simmler&author=M%20Ineichen&author=E%20Grouzmann&author=MC%20Hoener&volume=90&publication_year=2011&pages=246-255&pmid=21677639&doi=10.1038/clpt.2011.78&)

7. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al. Duloxetine inhibits effects of MDMA (‘ecstasy’) in vitro and in humans in a randomized placebo-controlled laboratory study. PloS One 2012; 7:e36476.  [DOI](https://doi.org/10.1371/journal.pone.0036476) | [PMC free article](/articles/PMC3344887/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22574166/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PloS%20One&title=Duloxetine%20inhibits%20effects%20of%20MDMA%20(%E2%80%98ecstasy%E2%80%99)%20in%20vitro%20and%20in%20humans%20in%20a%20randomized%20placebo-controlled%20laboratory%20study&author=CM%20Hysek&author=LD%20Simmler&author=V%20Nicola&author=N%20Vischer&author=M%20Donzelli&volume=7&publication_year=2012&pages=e36476&pmid=22574166&doi=10.1371/journal.pone.0036476&)

8. Antolino-Lobo I, Meulenbelt J, Nijmeijer SM, Scherpenisse P, van den Berg M, van Duursen MB. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab Dispos 2010; 38:1105–1112.  [DOI](https://doi.org/10.1124/dmd.110.032359) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20388857/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&title=Differential%20roles%20of%20phase%20I%20and%20phase%20II%20enzymes%20in%203,4-methylendioxymethamphetamine-induced%20cytotoxicity&author=I%20Antolino-Lobo&author=J%20Meulenbelt&author=SM%20Nijmeijer&author=P%20Scherpenisse&author=M%20van%20den%20Berg&volume=38&publication_year=2010&pages=1105-1112&pmid=20388857&doi=10.1124/dmd.110.032359&)

9. De la Torre R, Farré M, Mathúna BO, Roset PN, Pizarro N, Segura M, et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 2005; 61:551–554.  [DOI](https://doi.org/10.1007/s00228-005-0965-y) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16041599/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Clin%20Pharmacol&title=MDMA%20(ecstasy)%20pharmacokinetics%20in%20a%20CYP2D6%20poor%20metaboliser%20and%20in%20nine%20CYP2D6%20extensive%20metabolisers&author=R%20De%20la%20Torre&author=M%20Farr%C3%A9&author=BO%20Math%C3%BAna&author=PN%20Roset&author=N%20Pizarro&volume=61&publication_year=2005&pages=551-554&pmid=16041599&doi=10.1007/s00228-005-0965-y&)

10. Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos 2008; 36:2345–2354.  [DOI](https://doi.org/10.1124/dmd.108.021543) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18725511/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&title=The%20role%20of%20human%20hepatic%20cytochrome%20P450%20isozymes%20in%20the%20metabolism%20of%20racemic%203,4-methylenedioxy-methamphetamine%20and%20its%20enantiomers&author=MR%20Meyer&author=FT%20Peters&author=HH%20Maurer&volume=36&publication_year=2008&pages=2345-2354&pmid=18725511&doi=10.1124/dmd.108.021543&)

11. Gilhooly TC, Daly AK. CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 2002; 54:69–70.  [DOI](https://doi.org/10.1046/j.1365-2125.2002.01574.x) | [PMC free article](/articles/PMC1874389/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/12100228/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&title=CYP2D6%20deficiency,%20a%20factor%20in%20ecstasy%20related%20deaths?&author=TC%20Gilhooly&author=AK%20Daly&volume=54&publication_year=2002&pages=69-70&pmid=12100228&doi=10.1046/j.1365-2125.2002.01574.x&)

12. Yubero-Lahoz S, Pardo R, Farre M, Mathuna BÓ, Torrens M, Mustata C, et al. Changes in CYP1A2 activity in humans after 3,4-methylene-dioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metab Pharmacokinet 2012; 27:605–613.  [DOI](https://doi.org/10.2133/dmpk.dmpk-12-rg-032) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22673010/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Pharmacokinet&title=Changes%20in%20CYP1A2%20activity%20in%20humans%20after%203,4-methylene-dioxymethamphetamine%20(MDMA,%20ecstasy)%20administration%20using%20caffeine%20as%20a%20probe%20drug&author=S%20Yubero-Lahoz&author=R%20Pardo&author=M%20Farre&author=B%C3%93%20Mathuna&author=M%20Torrens&volume=27&publication_year=2012&pages=605-613&pmid=22673010&doi=10.2133/dmpk.dmpk-12-rg-032&)
